Clínica Baviera stock: fair value
CBAV.MCThe fair value of Clínica Baviera under our model is $69.08, the price is 15% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $53.14 and expensive above $98.69 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $75.21 (cash-flow model) and $62.95 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8%. At 9% the fair value would be $62.79, at 7% it would be $78.53.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 3.0%. Discounted at 8.0% (floor: government bond yield 3.0% plus 5 percentage points, since beta 0.8 times the risk premium would give less); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $75.21 per share: free cash flow for the next ten years, each year discounted to today at 8.0%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 8.0%) |
|---|---|---|---|---|
| 2026 | $58.17M | extrapolated at 4.8% | 0.9263 | $53.88M |
| 2027 | $60.64M | extrapolated at 4.3% | 0.8580 | $52.03M |
| 2028 | $62.99M | extrapolated at 3.9% | 0.7947 | $50.06M |
| 2029 | $65.25M | extrapolated at 3.6% | 0.7361 | $48.03M |
| 2030 | $67.47M | extrapolated at 3.4% | 0.6818 | $46M |
| 2031 | $69.68M | extrapolated at 3.3% | 0.6316 | $44.01M |
| 2032 | $71.89M | extrapolated at 3.2% | 0.5850 | $42.06M |
| 2033 | $74.13M | extrapolated at 3.1% | 0.5419 | $40.17M |
| 2034 | $76.4M | extrapolated at 3.1% | 0.5019 | $38.35M |
| 2035 | $78.72M | extrapolated at 3.0% | 0.4649 | $36.6M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $451.17M |
| Terminal value: cash flow 2035 × (1 + 3.0%) / (8.0% − 3.0%) | $1.62B |
| Present value of terminal value (× 0.4649) | $753.61M |
| Equity value (sum plus present value of terminal value) | $1.2B |
| Shares (diluted) | 16.02M |
| Value per share (equity value divided by shares) | $75.21 |
| Earnings per share, last twelve months | $3.21 |
| × 19.6 (industry P/E) | $62.95 |
| Fair value (average of both parts) | $69.08 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Dec 2020)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.